Clinical Trial

Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

Name: Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors — clinical trial record (NCT06963281)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-04-30.

Trial Details

NCT Number	NCT06963281
Lead Sponsor	Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. Collaborators: Fortvita Biologics (USA)Inc.
Conditions	Solid Tumors
Enrollment	285 participants
Start Date	2025-04-29
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-03-31 (estimated)
Updated on ClinicalTrials.gov	2025-06-06